Renata PLC

Renata PLC maintains a debt-to-equity ratio of 0.52, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.37, suggesting it can cover its short-term liabilities but with limited surplus. Free cash flow is negative at -1463667900 BDT, reflecting capital expenditure outpacing operating cash flow. Profitability metrics show a return on equity of 10.67% and a return on assets of 6.37%, both of which are in line with the industry's preferred metrics for pharmaceutical firms. The company's operating income of 5318828090 BDT and net income of 3615814030 BDT indicate a healthy margin, though the gross profit of 16677948460 BDT suggests room for improvement in cost management. Renata PLC operates in a diversified manner, with offerings spanning anthelmintic, live vaccines, nutrition products, vitamins & minerals, anti-gout, anti-spasmodic, and anti-allergic products. The company's revenue is primarily concentrated in Bangladesh, with no disclosed international revenue segments. This geographic concentration may expose the company to local economic and regulatory risks. The company's revenue growth trajectory is not explicitly provided, but the capital expenditure of -5948716510 BDT indicates ongoing investment in its manufacturing capabilities. Analysts have provided a mean price target of 642.33 BDT, with a median of 617.00 BDT, suggesting a generally positive outlook despite the absence of strong-buy recommendations. Risk factors include a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to fund operations without external financing. No significant dilution sources are identified in the current data, and the dilution potential is assessed as low. Recent events include the company's continued investment in manufacturing facilities and a stable analyst recommendation with three "buy" ratings. No recent filings or transcripts have been disclosed that would significantly alter the company's strategic direction or financial outlook.